Clinical Trial Update: Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema [Phase 4]

View source ↗

Summary

Phase 4 trial assessing combination OZURDEX and LUCENTIS versus OZURDEX alone in incomplete responders with diabetic macular edema was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Lucentis (ranibizumab)
• Ozurdex (dexamethasone intravitreal implant)

Snippet

Sponsor: North Toronto Eye Care Laser and Eye Specialists | Conditions: Diabetic Macular Edema | Phase 4 | Status: TERMINATED